We performed a randomized, comparative study to evaluate the effects of VCZ and liposomal Amp-B in an experimental endophthalmitis model. A. fumigatus is the most common fungal pathogen in endophthalmitis and causes a rapid, progressive infection. In this trial, fungal endophthalmitis in guinea pigs was induced via an intravitreal injection of 1.0 × 106 CFU/mL A. fumigatus. Three days following incubation with A. fumigatus, all eyes demonstrated slight to mild diffuse inflammatory reactions. The inflammation was exacerbated on day 5 (gradual enlargement of corneal edema, anterior purulent exudation, and vitreous haze). Ten days later, we observed corneal neovascularization and anterior chamber hypopyon. Clinical deterioration was observed 4 weeks later (two cases of ocular atrophy with panendophthalmitis). The retinal histopathologic findings suggested severe inflammation with destruction of the retinal architecture. The clinical observations, histopathologic studies, positive cultures, and smears of vitreous specimens demonstrated that the A. fumigatus endophthalmitis was successfully modeled.
Several studies indicate that intravitreal injection of Amp-B or VCZ effectively treats fungal endophthalmitis.
8,15–17 This study compared the in vivo antifungal effects of VCZ and liposomal Amp-B against
A. fumigatus in exogenous endophthalmitis in guinea pig eyes.
In a guinea pig model of invasive
A. fumigatus, both VCZ and liposomal Amp-B demonstrated antifungal effects. No significant differences were detected between the VCZ group and the liposomal Amp-B group regarding clinical degradation and ERG results on days 1 and 3. The differences in corneal opacity (
P < 0.05 on days 7 and 10), aqueous flare (
P < 0.05 on days 7, 10, and 14), and vitreous opacity (
P < 0.05 on days 5 and 7), as well as ERG recordings of b-wave amplitudes (
P < 0.05 on days 3, 7, and 14) and latency (
P < 0.05 on day 14), were significantly different between the two groups. This result indicates that liposomal Amp-B was less effective than VCZ at similar doses. According to the clinical grading and ERG examinations, treatment with VCZ during the early and middle stages led to better responses than liposomal Amp-B. These results are consistent with a previously published comparison of VCZ and Amp-B for the treatment of invasive
Aspergillus.
19 We acknowledge that the histopathology and electrophysiology were analyzed in only two animals from each group. Thus, the results could be more conclusive if the histopathology and electrophysiology were examined in a larger number of animals. There were no significant differences in the late stage. In this study, VCZ and liposomal Amp-B did not cause retinal toxicity (ERG or histopathologic studies) when the intravitreal dose was 20 μg/0.02 mL. Our results suggested that VCZ and liposomal Amp-B were equally effective during the late stage of exogenous
A. fumigatus infection with better outcomes and no recurrence. In contrast, initial therapy with VCZ was superior to liposomal Amp-B.
The initial inferiority of liposomal Amp-B could be explained by the membrane-stabilizing effect of cholesterol. Liposomal Amp-B consists of Amp-B and unilamellar liposomes containing cholesterol.
20 When the fungal cells attach to liposomal Amp-B, as an active antifungal ingredient, Amp-B will be released from the liposome.
21 Amphotercercin B increases the membrane permeability and leakage of cellular components. These actions cause fungal cell death through ergosterol binding, which is an integral component of the fungal cell wall.
13 Liposomal Amp-B may have a delayed efficacy due to the cholesterol contained within the liposomes.
15 Alternatively, this difference could be partially due to the contact between liposomal Amp-B and its target. Intravitreal administration of liposomal Amp-B away from the lesion could result in low drug availability, which might contribute to the decreased effects of liposomal Amp-B for acute infections. In contrast, VCZ inhibits ergosterol biosynthesis in the fungal cell wall and subsequent cell death through direct inhibition of lanosterol demethylation.
4 Additionally, the MIC values of the two drugs were different. Therefore, VCZ was superior to liposomal Amp-B for the treatment of acute
A. fumigatus infection.
In summary, both intravitreal VCZ and liposomal Amp-B were effective antifungal agents for exogenous A. fumigatus endophthalmitis. However, VCZ was superior to liposomal Amp-B at a similar dose (as an initial therapy) for acute infections. Further experimental and clinical studies are required to confirm the efficacy of these two antifungal drugs.